Form 4: Kymera COO Acquires Equity, Sells Shares for Tax

Kymera Therapeutics' Chief Operating Officer, Jeremy G. Chadwick, acquired new restricted stock units and stock options while selling shares to cover tax withholding obligations.

Summary

• Jeremy G. Chadwick, Chief Operating Officer of Kymera Therapeutics, Inc. (KYMR), acquired 12,575 restricted stock units (RSUs) on March 2, 2026.
• These RSUs represent a contingent right to receive one share of common stock upon vesting and settlement, vesting in three equal annual installments following March 3, 2025.
• Chadwick also acquired 25,150 stock options on March 2, 2026, with an exercise price of $90.1.
• These stock options vest in 48 equal monthly installments following March 2, 2026, and expire on March 1, 2036.
• To cover tax withholding obligations related to RSU vesting, Chadwick sold a total of 5,908 shares of common stock across multiple transactions on March 2, 2026, and March 4, 2026.
• The sales occurred at weighted average prices ranging from $83.9965 to $89.6574 per share.
• Following these transactions, Chadwick beneficially owns 73,810 shares of common stock and 25,150 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While there were sales of shares, they were non-discretionary for tax purposes, and the significant grants of new RSUs and stock options indicate continued executive alignment and long-term incentive.

Positives

• Acquisition of 12,575 restricted stock units (RSUs) by the Chief Operating Officer, aligning executive interests with shareholder value.
• Grant of 25,150 stock options to the Chief Operating Officer, providing long-term incentive and demonstrating continued commitment.

Future Outlook

The acquired restricted stock units are scheduled to vest in three equal annual installments following March 3, 2025, subject to continued employment. The acquired stock options will vest in 48 equal monthly installments following March 2, 2026, also contingent on continued employment.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units and stock options to a Chief Operating Officer is a standard practice in the biotechnology and pharmaceutical industry for executive compensation, aiming to align management incentives with long-term company performance and shareholder value. These types of equity awards are common across companies like Moderna, BioNTech, and Regeneron, reflecting a broader industry trend of using equity to attract and retain top talent.

Comparison to Industry Standards

• The structure of equity compensation, including RSUs vesting over several years and stock options with a multi-year vesting schedule, is consistent with executive compensation packages observed at comparable biotech firms such as Vertex Pharmaceuticals and Gilead Sciences, which also utilize long-term equity incentives to retain key personnel.
• The sale of shares solely for tax withholding purposes upon RSU vesting is a routine and expected event for executives receiving equity compensation, aligning with practices seen at companies across various sectors, including tech giants like Apple and Amazon, where executives often sell a portion of vested shares to cover statutory tax obligations.

Related Party Transactions

• The acquisition of 12,575 restricted stock units and 25,150 stock options by the Chief Operating Officer from Kymera Therapeutics, Inc.
• The sale of 5,908 shares of common stock by the Chief Operating Officer to cover tax withholding obligations related to RSU vesting.

Stakeholder Impact

• Shareholders: The grants of equity awards align the Chief Operating Officer's interests with long-term shareholder value. The tax-related sales are routine and do not signal a lack of confidence.
• Employees: The equity grants reflect standard compensation practices for executives, potentially setting a precedent for other high-level employees.

Next Steps

• Continued vesting of 12,575 restricted stock units in three equal annual installments following March 3, 2025.
• Continued vesting of 25,150 stock options in 48 equal monthly installments following March 2, 2026.

Key Dates

Recommendation

The filing details routine executive compensation in the form of RSU and stock option grants, along with non-discretionary sales to cover tax obligations. These transactions do not provide a strong signal for a discretionary investment decision, thus a 'hold' recommendation is appropriate as they reflect standard corporate practices rather than a change in fundamental outlook or insider sentiment.

Keywords

Kymera Therapeutics, KYMR, Jeremy G. Chadwick, Chief Operating Officer, Insider Trading, Form 4, Restricted Stock Units, Stock Options, Equity Compensation, Tax Withholding